<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark), used extensively for the management of <z:e sem="disease" ids="C0684275,C0019069" disease_type="Disease or Syndrome" abbrv="">hemophilia</z:e> patients with inhibitors, has also been shown to be effective in the treatment of severe <z:mp ids='MP_0001914'>bleeding</z:mp> episodes and for coverage of surgical procedures in patients with <z:e sem="disease" ids="C0005818" disease_type="Disease or Syndrome" abbrv="">platelet disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Cases include seven patients with congenital <z:e sem="disease" ids="C0005818" disease_type="Disease or Syndrome" abbrv="">platelet disorders</z:e> [<z:e sem="disease" ids="C0235604" disease_type="Disease or Syndrome" abbrv="">Glanzmann</z:e> <z:hpo ids='HP_0004807'>thrombasthenia</z:hpo> (n = 5), <z:e sem="disease" ids="C0005129" disease_type="Disease or Syndrome" abbrv="">Bernard-Soulier syndrome</z:e> (n = 1), platelet type (pseudo-) <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand disease</z:e> (n = 1)] and two patients with <z:e sem="disease" ids="C1264032" disease_type="Disease or Syndrome" abbrv="">acquired thrombocytopathy</z:e> associated with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:mp ids='MP_0009644'>uremia</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The clinical efficacy of rFVIIa in functional <z:e sem="disease" ids="C0005818" disease_type="Disease or Syndrome" abbrv="">platelet disorders</z:e> has been reported as good or excellent, although some cases of ineffectiveness exist </plain></SENT>
<SENT sid="3" pm="."><plain>The agent is well tolerated with a single published case of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> as a postoperative complication </plain></SENT>
<SENT sid="4" pm="."><plain>In addition to these reported cases, there are others that remain unreported and unpublished </plain></SENT>
<SENT sid="5" pm="."><plain>An International Registry on Recombinant Factor VIIa and Congenital <z:e sem="disease" ids="C0005818" disease_type="Disease or Syndrome" abbrv="">Platelet Disorders</z:e> (forms in Appendix 1) has been established to obtain more safety and efficacy data on patients with congenital <z:e sem="disease" ids="C0005818" disease_type="Disease or Syndrome" abbrv="">platelet disorders</z:e> treated with NovoSeven </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis of data from this larger population will allow better comprehension of the role of NovoSeven in these disorders, and assist in the design of formal studies to address issues associated with the treatment of these disorders </plain></SENT>
</text></document>